XML 49 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statement of Operations (Unaudited) (USD $)
 3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Statement of Operations [Abstract]    
Revenues    $ 31,558
Cost of Goods Sold 17,739 15,360
Gross Income(Loss) (17,739) 16,198
Operating Expenses    
General and Administrative Expenses 326,428 175,016
Depreciation and Amortization 6,794 8,600
Consulting Expenses 61,145 13,048
Total Operating Expense 394,367 196,664
(LOSS) FROM OPERATIONS (412,106) (180,466)
Other Income (Expense)    
Interest (expense) (13,999) (159,922)
Gain (loss) on Currency Transactions    (100,327)
Gain on Derivative Liability    41,643
Interest Income 51   
Total Other Income (Expense) (13,948) (218,606)
(Loss) Before Income Taxes (426,054) (399,072)
Income Tax Expense (Benefit)      
NET (LOSS) (426,054) (399,072)
LESS NET LOSS ATTRIBUTABLE TO NON-CONTROLLED INTEREST IN SUBSIDIARY      
NET (LOSS) ATTRIBUTABLE TO NON CONTROLLED DANDRIT BIOTECH USA, INC. $ (426,054) $ (399,072)
BASIC AND DILUTED LOSS PER SHARE $ (0.06) $ (0.08)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED 6,880,278 5,133,096